News Article | February 28, 2017
According to a new market research report "Cognitive Assessment and Training in Healthcare Market by Assessment Type (Pen-and-Paper Based, Hosted, and Biometrics), Components, Application (Clinical Trial, Screening & Diagnostics, Brain Training, Academic Research), & Region - Global forecast to 2021", published by MarketsandMarkets, the market size estimated to grow from USD 962.0 Million in 2016 to USD 4,127.2 Million by 2021, at a Compound Annual Growth Rate (CAGR) of 33.8%. Browse 56 market data Tables and 44 Figures spread through 138 Pages and in-depth TOC on "Cognitive Assessment and Training in Healthcare Market" http://www.marketsandmarkets.com/Market-Reports/cognitive-assessment-training-healthcare-market-191532711.html Early buyers will receive 10% customization on this report. The major forces driving this market are aging global population, increasing awareness about brain fitness, and advancements in technology. The growing market for cognitive solutions and increasing demand for brain training by next-generation tech-savvy population are contributing to the growth of the Cognitive Assessment and Training in Healthcare Market. Clinical trials in terms of application is expected hold the largest market share in the Cognitive Assessment and Training in Healthcare Market during the forecast period Clinical trials are mainly used to identify, measure, or monitor cognitive impairments and cognitive changes. The assessment of cognitive functions is an integral part of decision making during clinical drug development, as certain drugs can have an impact on the cognitive capabilities of the brain. The market is expected to contribute the highest revenue for vendors offering clinical trials. Service segment is expected to grow at the highest CAGR in the Cognitive Assessment and Training in Healthcare Market and the current trend is expected to continue during the forecast period An Increasing demand for cognitive assessment and training tests and procedures in the global healthcare market also provides a significant scope for associated services as well. The growth of the services segment is expected to accelerate, due to an increasing level of awareness regarding the brain fitness. With the increasing utilization of cognitive assessment and training solutions, the services act as an add-on to these solutions making them more valuable. Providers of cognitive assessment and training solutions and services offer training and coaching services to deliver balanced cognitive rehabilitation solutions. North America is expected to contribute the largest market share and Asia-Pacific (APAC) to grow at the highest rate North America is expected to hold the largest market share and to dominate the Cognitive Assessment and Training in Healthcare Market from 2016 to 2021, due to the increasing awareness among population about adopting medication for cognitive diseases. The new generation in this region is more concerned towards the benefits of cognitive training, which is not just limited to patients with cognitive dysfunctions. The U.S. market holds a majority of the market share in terms of adoption as well as revenue generation in the North American market, due to the rapidly aging population vulnerable to cognitive diseases in the region. The APAC region is expected to witness the highest growth rate during the forecast period, as the population in the region is more inclined towards adopting a healthier lifestyle. Hence, the concerns regarding cognitive diseases are growing in the region. The major vendors in the Cognitive Assessment and Training in Healthcare Market include Cambridge Cognition Ltd. (Cambridge, U.K.), Cogstate Ltd. (New Haven, U.S.), Bracket (Pennsylvania, U.S.), MedAvante Inc. (New Jersey, U.S.), Quest Diagnostic (New Jersey, U.S.), ProPhase, LLC (New York, U.S.), CogniFit (New York, U.S.), ERT Clinical (Pennsylvania, U.S.), NeuroCog Trials (North Carolina, U.S.), and Brain Resource Company (New South Wales, Australia). Cognitive Computing Market by Technology (Natural Language Processing, Machine Learning, Automated Reasoning), by Deployment Model (On-Premises, Cloud) & by Regions - Global Forecast to 2019 http://www.marketsandmarkets.com/Market-Reports/cognitive-computing-market-%20136144837.html Cognitive Assessment and Training Market by Assessment Type (Pen & Paper Based, Hosted, Biometrics), Service, Application (Clinical Trials, Classroom Learning, Brain Training, Corporate Learning, Academic Research), Vertical and Region - Global Forecast to 2020 http://www.marketsandmarkets.com/Market-Reports/cognitive-assessment-market-1039.html Know More About our Knowledge Store @ http://www.marketsandmarkets.com/Knowledgestore.asp MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Visit MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/market-reports/telecom-it Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
News Article | May 23, 2017
Louis Gagnon recently joined the MyBrainSolutions (MBS) team as CEO. Gagnon has 25 years of experience as a high-growth global digital businesses leader, most notably at Amazon’s subsidiary Audible where he served as Chief Product and Marketing Officer. He also was recently appointed Advisor to TPG Capital following a short CEO assignment to turn around portfolio company Ride.com. Other past notable roles include Chief Product & Marketing Officer at Yodle and Senior VP of Global Products at Monster Worldwide. As the new CEO of MBS and Brain Resource Limited, Gagnon intends to leverage the company’s valuable assets to accelerate momentum of 60% YoY revenue growth. More specifically, the company’s Holistic Brain Assessment/Training tools and its standardized Neuroscientific Database will be used to empower individuals to assess and optimize the core brain processes that power their wellbeing. “I have spent my career focused on creating social change while generating successful shareholder outcomes,” said Gagnon. “Brain Resource is the largest shareholder value creation opportunity that I have been associated with and it also is the largest social change opportunity. I am very humbled and grateful for the work that has led us here and I cannot be more excited to build the team and execute the strategy that will take this great work to the next level.” Added MBS Chairman and co-founder Dr. Evian Gordon, “Louis is an extremely well-credentialed leader of high-growth technology-based companies who has a significant personal interest in brain performance. He has extensive relationships across the technology and investment community and provides shareholders with a proven track record of establishing market adoption and repeat purchase of innovative products in high frequency.” Another new addition, Emil Vasilev, comes to MBS with well-rounded experiences across the technology, private equity and investment banking arenas. Having worked as an investment banker at Barclays Capital and investor at Corsair Capital, Vasilev brings in-depth knowledge of finance, capital raising, transaction execution and strategy. He also has hands-on experience overseeing the finance and operations functions at Ride, a portfolio company of TPG Growth. Vasilev has expressed enthusiasm to align with MBS at a time when the importance of a holistic approach to the brain, corporate and personal well-being is becoming the norm among corporates and business leaders around the world. “I am excited to join MBS and help execute the new plan for the company while leveraging its existing marquee assets,” concluded Vasilev. “Their scientific foundation and blue-chip client base are testament to the significant opportunity for shareholder and social value-creation.” Vasilev is an eager practitioner of mindfulness meditation and holistic brain practices and volunteers as a teacher of stress management techniques and meditation. He holds a Bachelor’s degree in Economics from Amherst College. About MyBrainSolutions [parent company Brain Resource Ltd (ASX: BRC)] MyBrainSolutions is an online integrated self-empowerment platform to assess the brain and provide engaging digital health tools to train new habits and improve brain health. The platform is the first to bring together a brain-based assessment with tools to reduce stress and improve cognitive and emotional functions for employees and customers using scalable, confidential and cost-effective methods. MyBrainSolutions is owned by a subsidiary of Brain Resource Limited, which is also commercializing iSPOT products powered by the largest standardized and integrated database on the brain. For more information, please visit http://www.mybrainsolutions.com. About the NALA™ The NALA offers small and medium-sized businesses effective ways to reach customers through new media. As a single-agency source, the NALA helps businesses flourish in their local community. The NALA's mission is to promote a business' relevant and newsworthy events and achievements, both online and through traditional media. For media inquiries, please call 805.650.6121, ext. 361.
Spronk D.,Research Institute Brainclinics |
Arns M.,Research Institute Brainclinics |
Arns M.,University Utrecht |
Barnett K.J.,Brain Resource |
And 2 more authors.
Journal of Affective Disorders | Year: 2011
The aim of this study was to investigate if biomarkers in QEEG, genetic and neuropsychological measures are suitable for the prediction of antidepressant treatment outcome in depression. Twenty-five patients diagnosed with major depressive disorder were assessed twice, pretreatment and at 8-wk follow-up, on a variety of QEEG and neuropsychological tasks. Additionally, cheek swab samples were collected to assess genetic predictors of treatment outcome. The primary outcome measure was the absolute decrease on the HAM-D rating scale. Regression models were built in order to investigate which markers contribute most to the decrease in absolute HAM-D scores. Patients who had a better clinical outcome were characterized by a decrease in the amplitude of the Auditory Oddball N1 at baseline. The 'Met/Met' variant of the COMT gene was the best genetic predictor of treatment outcome. Impaired verbal memory performance was the best cognitive predictor. Raised frontal Theta power was the best EEG predictor of change in HAM-D scores. A tentative integrative model showed that a combination of N1 amplitude at Pz and verbal memory performance accounted for the largest part of the explained variance. These markers may serve as new biomarkers suitable for the prediction of antidepressant treatment outcome. © 2010 Elsevier B.V. All rights reserved.
Korgaonkar M.S.,University of Sydney |
Grieve S.M.,University of Sydney |
Grieve S.M.,Brain Resource |
Etkin A.,Stanford University |
And 5 more authors.
Neuropsychopharmacology | Year: 2013
Functional neuroimaging studies have implicated dysregulation of prefrontal circuits in major depressive disorder (MDD), and these circuits are a viable target for predicting treatment outcomes. However, because of the heterogeneity of tasks and samples used in studies to date, it is unclear whether the central dysfunction is one of prefrontal hyperreactivity or hyporeactivity. We used a standardized battery of tasks and protocols for functional magnetic resonance imaging, to identify the common vs the specific prefrontal circuits engaged by these tasks in the same 30 outpatients with MDD compared with 30 matched, healthy control participants, recruited as part of the International Study to Predict Optimized Treatment in Depression (iSPOT-D). Reflecting cognitive neuroscience theory and established evidence, the battery included cognitive tasks designed to assess functions of selective attention, sustained attention-working memory and response inhibition, and emotion tasks to assess explicit conscious and implicit nonconscious viewing of facial emotion. MDD participants were distinguished by a distinctive biosignature of: hypoactivation of the dorsolateral prefrontal cortex during working memory updating and during conscious negative emotion processing; hyperactivation of the dorsomedial prefrontal cortex during working memory and response inhibition cognitive tasks and hypoactivation of the dorsomedial prefrontal during conscious processing of positive emotion. These results show that the use of standardized tasks in the same participants provides a way to tease out prefrontal circuitry dysfunction related to cognitive and emotional functions, and not to methodological or sample variations. These findings provide the frame of reference for identifying prefrontal biomarker predictors of treatment outcomes in MDD. © 2013 American College of Neuropsychopharmacology. All rights reserved.
Baker L.M.,University of Missouri-St. Louis |
Williams L.M.,University of Sydney |
Williams L.M.,Brain Resource |
Korgaonkar M.S.,University of Sydney |
And 3 more authors.
Brain Imaging and Behavior | Year: 2013
Previous studies of early life trauma suggest that in addition to its emotional impact, exposure to early life stress (ELS) is associated with alterations in brain structure. However, little attention has been devoted to the relationship between emotional processing and brain integrity as a function of age of ELS onset. In the present study we examined whether ELS onset in older ages of youth rather than younger ages is associated with smaller limbic and basal ganglia volumes as measured by magnetic resonance imaging (MRI). We hypothesized that later age of manifestation during youth is associated with smaller volumetric morphology in limbic and basal ganglia volumes in adulthood. A total of 173 individuals were divided into three groups based on the age of self-reported ELS. The three groups included individuals only experiencing early childhood ELS (1 month-7 years, n = 38), those only experiencing later childhood ELS (8 years -17 years, n = 59), and those who have not experienced ELS (n = 76). Anterior cingulate cortex (ACC), hippocampus, amygdala, insula and caudate volumes were measured using a T1-weighted MRI. Analyses confirmed that later childhood ELS was associated with volumetric reductions in the ACC and insula volumes, while ELS experienced between the ages of 1 month and 7 years was not associated with lower brain volumes in these regions. The results may reflect the influence of more fully developed emotional processing of ELS on the developing brain and reinforce a body of research implicating both the ACC and insula in neuropsychiatric disorders and emotional regulation. © 2012 Springer Science+Business Media New York.
Korgaonkar M.S.,University of Sydney |
Grieve S.M.,University of Sydney |
Grieve S.M.,Brain Resource |
Koslow S.H.,Brain Resource |
And 5 more authors.
Human Brain Mapping | Year: 2011
White matter (WM) has been shown to be affected in elderly patients with major depressive disorders (MDD). There is only limited evidence of WM structural abnormalities in nongeriatric MDD patients. This study investigates WM microstructural integrity in nongeriatric MDD patients recruited as part of the International Study to Predict Optimized Treatment in Depression clinical trial and establishes the validity of diffusion tensor imaging measures for the investigation of depression. Baseline diffusion tensor imaging data from 29 nongeriatric MDD participants (11 with melancholia) and 39 healthy control participants were used in this analysis. We performed tract-based spatial statistics analyses to evaluate WM microstructural integrity (1) between all healthy controls and all MDD participants, (2) between melancholic and nonmelancholic MDD participants, and (3) between each subgroup (melancholic and nonmelancholic) and controls. Significant WM integrity deficits were seen only for the melancholic MDD participants compared with controls. Compared with controls, melancholic participants showed an average reduction of 7.8% in fractional anisotropy over WM regions associated with the limbic system, dorsolateral prefrontal cortex, thalamic projection fibers, corpus callosum, and other association fibers. These fractional anisotropy deficits were also associated with decreased axial and increased radial diffusivity in these WM regions, suggesting a pattern of decreased myelination or other degeneration change. Our findings of WM structural abnormalities associated with the limbic system, the frontal cortex, and the thalamus support the prevailing theory of limbic-dorsolateral prefrontal cortex-thalamic dysfunction in depression. Our results also suggest that these deficits are most prominent in the melancholic subtype of MDD. © 2010 Wiley Periodicals, Inc.
Day C.V.A.,University of Sydney |
Day C.V.A.,Brain Resource |
Williams L.M.,University of Sydney |
Williams L.M.,Stanford University
Expert Review of Neurotherapeutics | Year: 2012
Melancholia is typified by features of psychomotor slowing, anxiety, appetite loss and sleep changes. It is usually observed in 20-30% of individuals meeting diagnostic criteria for major depressive disorder (MDD). There is currently no agreement on whether melancholic MDD represents a distinct entity defined by neurobiological as well as clinical features or, rather, a specifier for MDD. This situation is reflected in the revisions to DSM, including in the DSM-5 due for release in 2013. With this context in mind, the authors review the origins of the construct of melancholia in MDD, its theoretical grounding and the defining characteristics that arose from this research. The authors then outline the state of knowledge on the neurobiology of melancholia. This second aspect is illustrative of the National Institutes of Mental Health's research domain criteria initiative, which offers a framework for redefining constructs along neurobiological dimensions. The authors also consider the outlook for identifying a useful biosignature of melancholia. © 2012 Expert Reviews Ltd.
Benes F.M.,Brain Resource |
Benes F.M.,Harvard University
Schizophrenia Research | Year: 2015
Postmortem studies have suggested that there is abnormal GABAergic activity in the hippocampus in schizophrenia (SZ). In micro-dissected human hippocampal slices, a loss of interneurons and a compensatory upregulation of GABAA receptor binding activity on interneurons, but not PNs, has suggested that disinhibitory GABA-to-GABA connections are abnormal in stratum oriens (SO) of CA3/2, but not CA1, in schizophrenia. Abnormal expression changes in the expression of kainate receptor (KAR) subunits 5, 6 and 7, as well as an inwardly-rectifying hyperpolarization-activated cationic channel (Ih3; HCN3) may play important roles in regulating GABA cell activity at the SO CA3/2 locus. The exclusive neurons at this site are GABAergic interneurons; these cells also receive direct projections from the basolateral amygdala (BLA). When the BLA is stimulated by stereotaxic infusion of picrotoxin in rats, KARs influence axodendritic and presynaptic inhibitory mechanisms that regulate both inhibitory and disinhibitory interneurons in the SO-CA3/2 locus. The rat model described here was specifically developed to extend our understanding of these and other postmortem findings and has suggested that GABAergic abnormalities and possible disturbances in oscillatory rhythms may be related to a dysfunction of disinhibitory interneurons at the SO-CA3/2 site of schizophrenics. © 2015 .
Hawley L.A.,Brain Resource
Journal of Social Work in Disability and Rehabilitation | Year: 2016
Traumatic brain injury (TBI) can result in long-term injury-related disabilities. Individuals with TBI and their families must often advocate for themselves to secure resources to address their postinjury needs. However, the ability to advocate may be compromised by the effects of the injury. The Self-Advocacy for Independent Life (SAIL) program aims to empower individuals and families with the skills of self-advocacy so they can navigate life after brain injury in a self-efficacious manner. 2016 Copyright © Taylor & Francis Group, LLC